OQS
EGRX

Occudo Quantitative Strategies’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Occudo Quantitative Strategies’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-19,373
Closed -$102K – 1056
2024
Q1 		$102K Sell
19,373
-26,343
-58% -$145K 0.02% 650
2023
Q4 		$239K Buy
+45,716
New +$451K 0.03% 602

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Occudo Quantitative Strategies's EGRX Position: Q2 2024 in Review

Occudo Quantitative Strategies sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2024, closing a stake of 19,373 shares — an estimated $102K sold.

Occudo Quantitative Strategies first reported a position in EGRX in Q4 2023 and held it in 2 quarters. The position peaked at $239K in Q4 2023. 75 funds tracked by Wall St. Rank hold EGRX as of Q2 2024.

  • Occudo Quantitative Strategies reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 19,373 Eagle Pharmaceuticals, Inc. shares in Q2 2024, an estimated $102K.
  • Occudo Quantitative Strategies first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2023 and held it in 2 quarters.
  • Occudo Quantitative Strategies's Eagle Pharmaceuticals, Inc. position peaked at $239K in Q4 2023.
  • 75 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2024.

Based on Occudo Quantitative Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.